RxDoctor Payments Data

John Cullen, MD

Neurology · Rochester, NYNPI 1366761991

Payments from drug & device makers

$1,367in general payments, 2019–2025

Across 30 payments — averaging $45.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$365
  • Alnylam Pharmaceuticals Inc.$272
  • Boston Scientific$123
  • Teva Pharmaceuticals USA, Inc.$99
  • UCB, Inc.$85
  • Pfizer$67
  • plus $356 from 15 others

What the payments were for

  • Speaking & faculty fees$24018%
  • Food & beverage$1,05777%
  • Education$705%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,367 in reported general payments places this provider in the 50th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$43,574
Medicare patients
253
Services billed
473

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OcrevusOcrelizumab16$578,321
Radicava OrsEdaravone32$453,816
GammaplexImmun Glob G(Igg)/Gly/Iga 0-5027$243,802
BotoxOnabotulinumtoxina81$103,825
Nurtec OdtRimegepant Sulfate84$101,838
Aimovig AutoinjectorErenumab-Aooe107$82,992
UbrelvyUbrogepant66$62,223
QuliptaAtogepant20$23,205
Dalfampridine ErDalfampridine43$18,596
Emgality PenGalcanezumab-Gnlm15$13,690
NeuproRotigotine11$12,478
Ajovy AutoinjectorFremanezumab-Vfrm18$11,943
Ajovy SyringeFremanezumab-Vfrm13$10,016
Carbidopa-LevodopaCarbidopa/Levodopa126$7,430
Entacapone15$6,635

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieBotox, Ubrelvy, Qulipta$16$189,253167 claims
PfizerNurtec Odt$67$101,83884 claims
UCB, Inc.Neupro$85$12,47811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,623 neurology providers in New York.

Other neurology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →